ACCC

Search Drug Alphabetically

Generic Name	Erdafitinib
Brand Name	Balversa™
Payment Category	Medicare Part D
Year Introduced	2019
Type of Drug	Kinase inhibitor
Manufacturer	Janssen Biotech
Medical Affairs Questions (date verified)	800.526.7736
Coverage & Reimbursement Questions	866.378.1910
FDA-Approved Indication(s) Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have FGFR3 or FGFR2 genetic alterations and have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Balversa. (4/12/19)
Approved Indication(s) with Orphan Drug Status	None
ICD-10 Code(s) for Labeled Indication(s)	Malignant neoplasm of ureter [C66.x]; Malignant neoplasm of bladder [C67.x]; Malignant neoplasm of other and unspecified urinary organs [C68.x]

Name	Strength	Form	Package	Labeler	NDC